


Advanced Addiction Psychopharmacology 2026 Syllabus



Accreditation Statement

In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Target Audience Statement

This intensive online course is designed for physicians and other health care professionals who have a foundation in prescribing medication for patients with substance use disorders, including those with co-occurring psychiatric conditions, but would like a deeper understanding of these pharmacotherapies. Credit for this activity is designated for learners in the following ways:

Physician Designation Statement

American Academy of Addiction Psychiatry designates this Other activity (one portion of this course is an independent online activity and another portion of this course is a live face-to-face educational exchange with a clinical expert responding to learner questions) for a maximum of 14.75 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Health Professionals Designation Statement

Participants will receive a Certificate of Attendance stating this program is designated for 14.75 *AMA PRA Category 1 Credits*™. This credit is accepted by the AANP and the AAPA.

Credits subject to change

Educational Objectives

Learners who attend this activity will receive a more in-depth educational experience in the pharmacotherapy of substance use disorders and co-occurring conditions, and after participating in this course, learners should be able to:

- Discuss the pharmacotherapy of bipolar disorder and schizophrenia in patients with co-occurring substance use disorders.
- List evidence-based options for anti-depressant and anti-anxiety pharmacotherapy when treating patients with co-occurring substance use disorders.
- Discuss evidence-based pharmacotherapy for treatment of ADHD with co-occurring substance use disorders.

- Understand how pharmacotherapy of substance use disorders is modified in the face of medical co-morbidities.
- Discuss evidence-based pharmacotherapy for treatment of PTSD with co-occurring substance use disorders.
- Discuss evidence-based pharmacotherapy for treatment of insomnia with co-occurring substance use disorders.
- Discuss evidence-based pharmacotherapy for treatment of substance use disorders in pregnancy.
- Discuss evidence-based pharmacotherapy for the treatment of substance use disorders in adolescents.

LIVE Q&A SESSIONS

Saturday, October 17th Presenter Time: 40 minutes each / Breaks: 15 minutes between sessions	
12:00 PM-12:05 PM	Welcome and Introduction to the Live Session John Mariani, MD, and Kevin Sevarino, MD, PhD
12:05 PM-12:45 PM	Pharmacotherapy of Substance Use Disorders in Adolescents Justine Welsh, MD
12:45 PM-1:00 PM	Break
1:00 PM-1:40 PM	Pharmacotherapy: Perinatal Substance Use Disorders Constance Guille, MD
1:40 PM-1:55 PM	Break
1:55 PM-2:35 PM	Pharmacotherapy of Depressive and Anxiety Disorders with Co-Occurring Substance Use Disorders Edward Nunes, MD
2:35 PM-2:50 PM	Break
2:50 PM-3:30 PM	Addiction Psychopharmacology of those with Co-Morbid Medical Conditions Kevin Sevarino, MD, PhD
3:30 PM-3:35 PM	End of the Day Wrap-Up
Sunday, October 18th Presenter Time: 40 minutes each / Breaks: 15 minutes between sessions	
12:00 PM-12:05 PM	Welcome and Introduction to the Live Session John Mariani, MD, and Kevin Sevarino, MD, PhD
12:05 PM-12:45 PM	Pharmacotherapy of Insomnia with Co-Occurring Substance Use Disorders Christina Brezing, MD
12:45 PM-1:00 PM	Break
1:00 PM-1:40 PM	Pharmacotherapy of Post-Traumatic Stress Disorder with Co-Occurring Substance Use Disorders Ismene Petrakis, MD
1:40 PM-1:55 PM	Break
1:55 PM-2:35 PM	Pharmacotherapy of Bipolar Disorder and Schizophrenia with Co-Occurring Substance Use Disorders John Mariani, MD
2:35 PM-2:50 PM	Break
2:50 PM-3:30 PM	Pharmacotherapy of ADHD with Co-Occurring Substance Use Disorders Frances Levin, MD

3:30 PM-3:35 PM	End of the Day Wrap-Up
-----------------	------------------------

On-Demand-Content:

On-Demand Content
Pharmacotherapy of Substance Use Disorders in Adolescents: Justine Welsh, MD
Pharmacotherapy: Perinatal Substance Use Disorders: Contance Guille, MD
Pharmacotherapy of Depressive and Anxiety Disorders with Co- Occurring Substance Use Disorders: Edward Nunes, MD
Pharmacotherapy of ADHD with Co-Occurring Substance Use Disorders: Frances Levin, MD
Pharmacotherapy of Insomnia with Co-Occurring Substance Use Disorders: Christina Brezing, MD
Pharmacotherapy of Post-Traumatic Stress Disorder with Co-Occurring Substance Use Disorders: Ismene Petrakis, MD
Pharmacotherapy of Bipolar Disorder and Schizophrenia with Co-Occurring Substance Use Disorders: John Mariani, MD
Addiction Psychopharmacology of those with Co-Morbid Medical Conditions: Kevin Sevarino, MD, PhD

Breakdown of Credit:

Maximum Credit	CME Credits
On-Demand	8.75
Saturday, October 17, 2026	3.00
Sunday, October 18, 2026	3.00
Grand total 14.75 <i>AMA PRA Category 1 Credits</i> TM	